by Mary Stuart
It is well known that obesity and type 2 diabetes often go hand-in-hand. Most type 2 diabetics are overweight, and...
Exploring the Bariatric Surgery/Diabetes Link: An Interview With Francesco Rubino, MD
Researchers have recently discovered that Roux-en-Y gastric bypass surgery is a very effective tool for improving-and sometimes completely reversing-type 2 diabetes. Medtech interviews Francesco Rubino, MD, chief of gastrointestinal metabolic surgery at Cornell University's Weill Cornell Medical College, who is at the forefront of a new subspecialty in bariatric surgery called diabetes surgery. He and his group are studying exactly how bariatric surgery succeeds in reversing type 2 diabetes.
More from Europe
• By
Increased support for NHS services and delivery infrastructure announced in the 11 June government spending review by chancellor of the exchequer Rachel Reeves could boost inward investment and offer new market opportunities for medtechs.
• By
Ahead of the 11 June UK spending review and its anticipated funding uplift for healthcare and life sciences, the MHRA announced an expansion of its digital expertise by creating a dedicated hub in Leeds, a renowned center of medtech excellence.
• By
Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.
• By
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
More from Geography
• By
Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.
• By
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
• By
FDA moves forward with implementing previous draft guidance and will consolidate forms, but the agency estimates limited impact in the total reporting burden.